Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Treatment options for advanced thyroid cancer refractory to standard therapies are limited. The safety and efficacy of pembrolizumab were evaluated in patients with advanced differentiated thyroid cancer expressing programmed death ligand 1 (PD-L1). | Safety and antitumor activity of the anti PD-1 antibody pembrolizumab in patients with advanced PD-L1 positive papillary or follicular thyroid cancer